Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9913909 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
US11253504 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
US10398686 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
US9744163 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
US9592227 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(11 years from now) | |
US10632199 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
US10898575 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
US11083797 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
US11083730 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
US10980886 | HERON THERAPS INC | Compositions of a polyorthoester and an organic acid excipient |
Apr, 2035
(12 years from now) | |
US11413350 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
US9694079 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
US9801945 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
US10213510 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) | |
US10098957 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | May 12, 2024 |
Market Authorisation Date: 12 May, 2021
Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation; Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures via instillation
Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic